Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs

PharmacoEconomics

Volumn 32, Issue 7, 2014, Pages 617-626

  Diel, R ^a   Lampenius, N ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC THERAPY; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEARS; GERMANY; HUMAN; INFECTION CONTROL; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MATHEMATICAL MODEL; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SCIENTIFIC LITERATURE; TUBERCULOSIS; COST BENEFIT ANALYSIS; DISABILITY; ECONOMICS; EUROPEAN UNION; FEMALE; HEALTH CARE COST; MALE; MORTALITY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; EUROPEAN UNION; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; MALE; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84904006945     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0159-5     Document Type: Review

References (45)

1. van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis. 2012;16:288-96.
2. D'Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med. 2012;367:2154 (author reply 2155-2156).
3. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: World Health Organization; 2013.
4. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: European Centre for Disease Prevention and Control; 2013.
5. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43:554-65.
6. Mwaba P, McNerney R, Grobusch MP, O'Grady J, Bates M, Kapata N, Maeurer M, Zumla A. Achieving STOP TB Partnership goals: perspectives on develop-ment of new diagnostics, drugs and vaccines for tuberculosis. Trop Med Int Health. 2011;16:819-27.
7. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, Deng S, Chen M. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect. 2012;64:580-8.
8. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-405.
9. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151-60.
10. NICE. Guide to the methods of technology appraisal. Issued: June 2008.
11. Miller TL, McNabb SJN, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS ONE. 2009;4:e5080.
12. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: European Centre for Disease Prevention and Control; 2012.
13. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71-9.
14. RKI. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2011. Robert Koch-Institut, Berlin; 2013.
15. Diel R, Rutz S, Castell S, Schaberg T. Tuberculosis: cost of illness in Germany. Eur Respir J. 2012;40:143-51.
16. Burden M, Bakere H. A Patient's journey. Tuberculosis. BMJ. 2012;345:e6713.
17. Baral SC, Aryal Y, Bhattrai R, King R, Newell JN. The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies. BMC Public Health. 2014;14:46.
18. Tsevat J, Taylor WC, Wong JB, et al. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137:215-22.
19. Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health. 2006;6:157.
20. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17:1531-7.
21. Holland DP, Gillian D, Sanders GD, Carol D, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179:1055-60.
22. Choi HW, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013;17:1328-35.
23. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med. 2009;169:179-87.
24. Guo N, Marra F, Marra CA. Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes. 2009;7:14.
25. Bauer M, Leavens A, Schwartzman K. A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Qual Life Res. 2013;22:2213-35.
26. Guo N, et al. Health state utilities in latent and active tuberculosis. Value Health. 2008;11:1154-61.
27. Dhingra VK, Rajpal S. Health related quality of life (HRQL) scoring in tuberculosis. Indian J Tuberc. 2003;50:99-104. (Pubitemid 36770228)
28. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-28.
29. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med. 2006;3:e241.
30. Winetsky DE, Negoescu DM, DeMarchis EH, Almukhamedova O, Dooronbekova A, Pulatov D, Vezhnina N, Owens DK, Goldhaber-Fiebert JD. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLoS Med. 2012;9:e1001348.
31. The World Bank. World Development Report 1993: investing in health World Bank and Oxford University Press; 1993.
32. Murray CJL, Lopez AD (eds). Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions (Global Burden of Disease and Injury Series). Boston (MA): Harvard School of Public Health, 1996
33. Prüss-Üstün A, Mathers C, Corvalán C, Woodward A. Introduction and methods: assessing the environmental burden of disease at national and local levels. Geneva: World Health Organization, 2003
34. Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M, editors. National burden of disease studies: a practical guide. 2nd ed. Geneva: World Health Organization; 2001.
35. Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden of disease: disability adjusted life year (DALY) [online]. Available from URL: http://www.mf.uni-lj.si/dokumenti/6b695fc9385e3e2ab8fb41ec7d34660d.pdf
36. Grosse SD, Lollar DJ, Campbell VA, Chamie M. Disability and disability-adjusted life years: not the same. Public Health Rep. 2009;124:197-202.
37. Murray CJL, Lopez AD (eds). Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 (Global Burden of Disease and Injury Series). Boston (MA): Harvard University Press, 1996.
38. Murray CJL. Global burden of disease - quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429-45. (Pubitemid 24234133)
39. Murray CJL, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ. 1994;72:495-509. (Pubitemid 24232515)
40. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326-31. (Pubitemid 32911160)
41. Tan-Torres Edejer T, Baltussen R, Adam T, et al. editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO, 2003.
42. Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva: World Health Organization, 2004:1-9.
43. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-223.
44. Salomon JA. New disability weights for the global burden of disease. Bull World Health Organ. 2010;88:879.
45. Choosing Interventions that are Cost-Effective (WHO-CHOICE): cost-effectiveness thresholds. Geneva: World Health Organization; 2012 (last access 30 December 2013). http://www.who.int/choice/costs/CER-thresholds/en/ index.html.